Testosterone enanthate injection USP, provides testosterone enanthate, a derivative of the primary endogenous androgen testosterone, for intramuscular administration. In their active form, androgens have a 17-beta-hydroxy group. Esterification of the 17-beta-hydroxy group increases the duration of action of testosterone; hydrolysis to free testosterone occurs in vivo. Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus Testosterone Enanthate can be given at intervals of two to four weeks.

Testosterone enanthate used in males to treat primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. In females: metastatic mammary cancer. Other methods of counteracting estrogen activity in cases of adrenalectomy, hypophysectomy, and/or antiestrogen therapy.

Boldenone undecylenate is a derivative of testosterone with similar androgenic activity and higher mytrophic activity. Boldenone undecylenate does not convert into estrogens and does not have estrogen-related side effects. Instead, boldenone undecylenate is converted by 5-alpha-reductase into dihydroboldenone and some of it's androgenic effect mediated by dihydroboldenone.

Boldenone undecylenate increases overall body metabolism rate and increases appetite. Increase in lean body mass and low side effects make this anabolic/androgenic steroid (AAS) a good therapeutic choice for age-related non-genomic muscle degenerative diseases like sarcopenia. The undecylenate ester extends half-life of boldenone in circulation, which, depending on dose, is approximately seven days.